Comparative Pharmacology
Head-to-head clinical analysis: OVIDREL versus REPRONEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVIDREL versus REPRONEX.
OVIDREL vs REPRONEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OVIDREL (choriogonadotropin alfa) acts as a luteinizing hormone (LH) agonist, binding to the LH/choriogonadotropin receptor on ovarian theca and granulosa cells, triggering ovulation and luteinization by inducing resumption of oocyte meiosis and follicle rupture.
REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing cAMP and promoting follicular development and estrogen synthesis.
250 mcg subcutaneously once daily for 7 days following recombinant FSH stimulation. Alternatively, a single 250 mcg subcutaneous dose is used to trigger final follicular maturation 24-48 hours after last gonadotropin dose.
Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.
None Documented
None Documented
The terminal elimination half-life is approximately 30 hours (range 20-48 hours) in healthy adults. This supports a single-dose regimen for final follicular maturation in assisted reproductive technology.
Terminal elimination half-life: 24-30 hours (menotropins); clinically, it supports daily dosing during ovarian stimulation
Primarily renal, with approximately 10% of the administered dose excreted unchanged in urine within 24 hours. The remainder undergoes metabolic degradation in the kidneys and liver.
Renal (approximately 80% as parent drug and metabolites); biliary/fecal (<5%)
Category C
Category C
Gonadotropin
Gonadotropin